The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines
Open accessPublished version of a preprint
Abstract
Adoptive cell transfer (ACT) is considered a promising modality for cancer treatment, but despite ongoing improvements, many patients do not experience clinical benefits. The tumor microenvironment is an important limiting factor in immunotherapy that has not been addressed fully in ACT treatments. In this study, we report that upregualtion of the immunosuppressive receptor programmed cell death-1 (PD-1) expressed on transferred T cells at the tumor site, in a murine model of ACT, compared with its expression on transferred T cells present in the peripheral blood and spleen. As PD-1 can attenuate T-cell-mediated antitumor responses, we tested whether its blockade with an anti-PD-1 antibody could enhance the antitumor activity of ACT in this model. Cotreatment with both agents increased the number of transferred T cells at the tumor site and also enhanced tumor regressions, compared with treatments with either agent alone. While anti-PD-1 did not reduce the number of immunosuppressive regulatory T cells and myeloid-derived suppressor cells present in tumor-bearing mice, we found that it increased expression of IFN-γ and CXCL10 at the tumor site. Bone marrow-transplant experiments using IFN-γR-/- mice implicated IFN-γ as a crucial nexus for controlling PD-1-mediated tumor infiltration by T cells. Taken together, our results imply that blocking the PD-1 pathway can increase IFN-γ at the tumor site, thereby increasing chemokine-dependent trafficking of immune cells into malignant disease sites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, mouse models have shown that local IFN-γ upregulation is essential for anti-PD-1-mediated tumor regression (89).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Self-citationExpression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Self-citation
Research works printed but not linked: 1
- Laszlo, 2010, Adoptive T cell therapy for metastatic melanoma: the MD Anderson experience, J Immunother, 33, 863
Cited by
Sorted by citations
Items 401–432 of 432
Seo, H., Kim, B., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2023) · doi:10.1158/2326-6066.c.6548926.v1
Seo, H., Kim, B., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2023) · doi:10.1158/2326-6066.c.6548926
Seo, H., Kim, B., Bae, E., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. (2023) · doi:10.1158/2326-6066.22538878
Progression of radio-labeled molecular imaging probes targeting chemokine receptors
Yi, H., Qin, L., Ye, X., Jinling, S., Ji, J., Ye, T., Li, J., & Li, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104266
Kit, O. I., Vladimirova, L. Y., Sagakyants, A. B., Zlatnik, E. Y., Викторовна, Т. А., Dzhenkova, E. A., Novikova, I. A., Shulgina, O. G., Ulyanova, E. P., Zakaryan, K. M., et al. (2024) · Современные проблемы науки и образования · doi:10.17513/spno.33487
Pham, J. P., Zdanska, O., Selga, M., Javier, J., O'Grady, A., Chin, V. T., Forstner, D. F., Hsu, E., & Liu, J. (2024) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15423_g
Isocitrate Dehydrogenase Defects In Gliomas: PATH For Potential Therapeutics Hasit Shah
Shah, H. (2024) · International journal of high school research · doi:10.36838/v6i7.8
The Black Hole of Immune Checkpoint Blocking Therapy for Gastric Cancer: Hyperprogressive Disease
Wang, Z., Ma, C., Maswikiti, E. P., Han, Q., He, L., Liu, B., Han, Z., & Chen, H. (2025) · Cancer Science · doi:10.1111/cas.70143
Jafari, H., Brown-Burke, F., Pray, B. A., Sloan, S. L., Helmig-Mason, J., Hout, I., Leon, S., Long, M., Chan, W. K., Hanel, W. G., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0534
Immunotherapy in the Treatment of Melanoma
Katsouda, A., Rallis, T., Gogakos, A. S., Theocharidis, V., Kanteres, T., Tzinevi, M., Passos, I. D., & Mironidou‐Tzouveleki, M. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1011805
Lee, P.-C., Li, P.-Y., Lee, C.-Y., Lin, S.-R., Wu, C., Hung, Y., Chen, Y.-H., Chan, J.-W., Mon, H.-C., Lee, C.-J., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14945-9
Xia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19641910
Self-citationXia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19641907
Self-citationXia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19641898
Self-citationXia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19641895
Self-citationXia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19641901
Self-citationDu, X., Wen, S., Shi, R., Xia, J., Wang, R., Zhang, Y., Pan, B., Wu, X., Zhu, W., Feng, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616218
Xia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19641892
Self-citationXia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19641904
Self-citationFlow Cytometry Analysis of IFNγ-Induced PD-L1 Cell Surface Expression in Ovarian Cancer Cells
Padmanabhan, S., Zou, Y., & Vancurova, I. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-4901-5_3
Yamada, T., Okuyama, K., Hamada, A., & Yanamoto, S. (2026) · Oral Oncology · doi:10.1016/j.oraloncology.2026.107958
Champiat, S. (2019) · theses.fr (ABES) · doi:10.70675/e358773dz1898z4feezbb3bzbdee7c7f20a6
Jia, D., Tan, W., Du, J., Zhang, J., Yan, X., Zhang, P., Liang, L., Wen, T., Duan, Y., Su, Y., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118101
Zhang, H., Ma, J., Shi, M., Chen, L., Zhang, Y.-F., Gao, Z., Wang, Z.-R., Liu, B., Luo, W., Pei, H., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01818-2
Dehkordi, S. H., & Arabameri, A. (2026) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2026.111906
Wang, B., Zhao, D., Ma, Y., & Sui, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1954319
Zhang, P., Wang, D., He, W., Zhang, H., Yumei, D. O. N. G., SiTu, Y., Wang, M., Zhang, Y., Shihong, W. E. I., Qiu, B., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-016467
BindingDB (2024) · UC San Diego · doi:10.7270/q2ff3xmh
Metadata
- Authors
- Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W. W., Lizée, G., Radvanyi, L., & Hwu, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Authors' Affiliations: 1Department of Melanoma Medical Oncology, The Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 2Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan
- Corresponding author
- Hwu, Patrick
- ORCID
- Venue
- Cancer Research
- Published
- 2012-10-14
- Volume
- 72
- Issue
- 20
- Pages
- 5209-5218
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC3476734
- OpenAlex
- W2116158418
- Cited by
- 432
- References
- 41
- Citations by year
- 2026: 18 · 2025: 25 · 2024: 27 · 2023: 38 · 2022: 47 · 2021: 31 · 2020: 30 · 2019: 40 · 2018: 38 · 2017: 34 · 2016: 33 · 2015: 34 · 2014: 17 · 2013: 18 · 2012: 2
- FWCI
- 11.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Japan Society for the Promotion of Science (22240089)
- National Cancer Institute (R01CA143077, CA 016672, R01CA123182, P01CA128913, R01CA116206, P30CA016672)
- National Center for Research Resources (UL1RR024148)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- anti-PD-1 therapy, adoptive cell transfer, interferon-gamma, CXCL10, chemokines, tumor microenvironment, regulatory T cells, myeloid-derived suppressor cells, IFN-gamma receptor, antitumor immunity, immune cell trafficking
- MeSH terms
- Animals, Cell Movement, Interferon-gamma, Mice, Transgenic, Neoplasms, Experimental, T-Lymphocytes, Up-Regulation, Lymphocytes, Tumor-Infiltrating, Chemokines, Adoptive Transfer, Cell Proliferation, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
